Cardiac resynchronization pacing without defibrillator capability: is this a viable option?

Creative Commons License

Ermis C., Benditt D. G.

EUROPACE, cilt.8, sa.7, ss.499-501, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 7
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1093/europace/eul047
  • Dergi Adı: EUROPACE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.499-501
  • Anahtar Kelimeler: implantable defibrillators, cardiac resynchronization, heart failure, quality-of-life, CHRONIC HEART-FAILURE, INTRAVENTRICULAR-CONDUCTION DELAY, DILATED CARDIOMYOPATHY, THERAPY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Improved cardiac resynchronization by pacemakers (CRT-P) and implantable defibrillators (CRT-D) benefits cardiac function, reduces heart failure (HF) admissions, and diminishes mortality in patients with severe left ventricutar (U) dysfunction. in terms of mortality benefit, current evidence suggests that CRT-D may be better than CRT-P alone when a broad range of HF patients is considered. However, the differential benefit may be small in certain patients. In individuals with severe and worsening HF due to systolic LV dysfunction, HF complications other than ventricular tachyarrhythmias contribute importantly to both quatity-of-tife (QoL) and duration of survival; these patients may be served cost-effectively by CRT-P enhancing QoL. A clinical trial evaluating CRT-D vs. CRT-P in terms of QoL and survival in such patients would assist physicians and payers to understand better the relative roles of CRT-P and CRT-D in the care of the sickest HF patients.